jacques genest rob welsh evidence based marketing
play

Jacques Genest, Rob Welsh Evidence-Based Marketing National - PowerPoint PPT Presentation

Harmonization of Guidelines: The C-CHANGE Initiative C anadian C ardiovascular HA rmonization of N ational G uidelines E ndeavour Acknowledgements Jacques Genest, Rob Welsh Evidence-Based Marketing National CPG Committee


  1. Harmonization of Guidelines: The C-CHANGE Initiative C anadian C ardiovascular HA rmonization of N ational G uidelines E ndeavour

  2. • Acknowledgements • Jacques Genest, Rob Welsh • Evidence-Based Marketing • National CPG Committee Memberships • Disclosures • Speaker/Advisory Board Honorariums • Research Funding - Sanofi • National CPG Committee Memberships • Canadian Diabetes Association 2013 • Canadian Cardiac Rehabilitation Cardiac Rehabilitation (Chair) • Canadian Hypertension Education Program • C-CHANGE (Canadian Cardiovascular HArmonization of National Guidelines Endeavour) (Chair) • CCS Dyslipidemia 2102 • CCS Smoking Cessation 2011 • CCS Committee on Chronic Stable Angina • CIHR Committee on Refractory Angina • Physical Activity for Adults 2011 • Physical Activity for Persons with Spinal Cord Dysfunction (Chair) 2011

  3. Overview • Who is C-CHANGE? • What is the history of C-CHANGE? • Why is C-CHANGE important? • What are the consequences of not realizing C-CHANGE? • The Update Process

  4. CPGs: Reality or Illusion?

  5. Who is C-CHANGE?

  6. C-CHANGE Partners 1. Canadian Association of Cardiac Rehabilitation 2. Canadian Diabetes Association 3. CCS Dyslipidemia Guidelines Group 4. Canadian Hypertension Education Program 5. Canadian Stroke Network 6. Canadian Society for Exercise Physiology 7. CCS Smoking Cessation Working Group 8. Obesity Canada 9. CCS Anti-Platelet Guidelines 10. CCS Heart Failure Guidelines 11. CCS Atrial Fibrillation Guidelines 12. CCS Stable Ischemic Heart Disease Guidelines

  7. What is the History of C-CHANGE? Why do we need Integrated CPGs?

  8. C-CHANGE History • 2002 – Campbell and Stone – September 2002 – SOLIDDE • 2003 – 2007 – Six meetings • 2008 – CIHR • Canadian Vascular Coalition – CPG Development

  9. C-CHANGE History • 2010 – June – Harmonization Meeting • 2011 – C-CHANGE Publication • 2014 - Update

  10. C-CHANGE History • 2010 – June – Harmonization Meeting • 2011 – C-CHANGE Publication • 2014 - Update

  11. Why IS C-CHANGE Important?

  12. Why is C-CHANGE Important? • Clinical Leadership – Knowledge of science leads to expertise in the art • Thought Leadership – Visionaries – Work horses – Collaborators • Research Leadership – Basic science – Clinical trails – Outcomes assessments • Primacy of Evidence-Informed Clinical Practice – Evidence informs experience – Enhanced experience leads to enhanced outcomes

  13. What are the Consequences of Not Realizing C-CHANGE? “ All for One and One for All! ”

  14. No C-CHANGE: Consequences • CPG anarchy – Competition for markets – Competition for funding – Competition for development stakeholders – Fragmentation of: • Prevention • Chronic disease care • Teaching and education • Sub-optimal patient outcomes • Primacy of practice-informed clinical practice – Experience is more important than evidence – Return to eminence-based practice • Recommendation Redundancy

  15. Recommendation Duplication Nutrition Source Guideline Recommendation (Location) CDA (Health In diabetes Adults with diabetes should consume no more than 7% of Behaviour total daily energy from saturated fats and should limit intake of trans Interventions) fatty acids to a minimum. (Grade D, Consensus) Obesity Canada A high-protein or a low-fat diet (within acceptable macronutrient (Health distribution ranges indicated in the Dietary Reference Intakes) is Behaviour suggested as a reasonable short-term (6 – 12 months) treatment option Interventions) for obese adults as part of a weight-loss program. (Grade B, Level 2) Obesity Canada Meal replacements may be considered as a component of an energy- (Health reduced diet for selected adults interested in commencing a dietary Behaviour weight-loss program. (Grade C, Level 2) Interventions)

  16. No C-CHANGE: Consequences

  17. Harmonized Recommendations Translating Scientific Knowledge into Clinical Action

  18. Recommendation Categories Diagnostic • Screening • Risk Stratification • Diagnostic Tests Therapeutic • Treatment Targets • Health Behaviour Therapies • Pharmacological Therapies

  19. The Update Process

  20. C-CHANGE Update Process 1. Harmonize specific recommendations - same wording 2. Do not increase the workload 3. Implementation tools must adhere strictly to the recommendations 4. All C-CHANGE implementation tools will have C-CHANGE branding 5. Recommendations development - include an implementability wording

  21. C-CHANGE Update Process 6 . Harmonized C-CHANGE recommendations reviewed annually 7. Guidelines development requires AGREE II 8. Bias reduction remains a constant priority 9. Core C-CHANGE implementation tools will not have industry support 10. Primary care physicians and allied health care professions: Recommendation Development Implementation Tool Development

  22. SUMMARY

  23. SUMMARY • Who is C-CHANGE? • What is the history of C-CHANGE? • Why C-CHANGE important? • What are the consequences of not realizing C-CHANGE? • The Update Process

  24. SUMMARY • The KT Ripple Effect – The Council of The Federation – Alberta Vascular Risk Reduction Project

  25. Summary

Recommend


More recommend